An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation.

Trial Profile

An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Ception Therapeutics
  • Most Recent Events

    • 23 Feb 2010 Status changed from recruiting to completed based on Cephalon/Ception Therapeutics media release.
    • 23 Feb 2010 Results reported in a Cephalon/Ception Therapeutics media release.
    • 11 Sep 2009 Additional lead trial investigator (Fahrenholz JM) added as reported by Vanderbilt University Institutional Review Board.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top